CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Non-Hodgkin Lymphoma
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Polatuzumab Vedotin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Retrovirally Naïve HIV+ Patients With Non-Hodgkin Lymphoma Can Be Treated With Standard Chemotherapy
Researchers investigated the efficacy and safety of CHOP-like therapy for treatment-naïve patients with simultaneous diagnoses of NHL and HIV-positive.
Improving the Clinical Diagnosis and Classification of Gray Zone Lymphomas
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Next post in Lymphoma
